KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

End-stage renal disease (ESRD) is defined as severe irreversible kidney damage, measured by the level of proteinuria and a reduction in the glomerular filtration rate to ˂15 ml/min/1.73 m2 ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.